Most algae founders building for the European food market have modelled their timelines around the wrong number.
The standard pitch deck assumption goes something like this: EFSA reviews novel food applications within nine months. The European Commission then has seven months to issue an implementing regulation. Total path to market: somewhere south of two years. This is what Regulation (EU) 2015/2283 promises on paper. It is not what happens.
The assumption that keeps failing
A July 2025 study published in npj Science of Food analysed every novel food application submitted to EFSA between 2018 and 2024 — 292 applications in total, the first systematic analysis of the framework's actual performance. The average time from submission to published EFSA opinion: 2.56 years. Some applications took six.
Add the Commission's seven-month implementation period after the opinion, and you are looking at a realistic floor of three-plus years between application and legal market access — for a product you may have started developing five years before that.
The gap between the statutory timeline and reality is not a minor administrative inconvenience. For a capital-intensive, pre-revenue algae company, it is a structural threat to existence.
Why the clock runs so much longer
The nine-month EFSA evaluation period is legally defined. It is also almost never observed, for a specific and well-understood reason: EFSA's right to issue Additional Data Requests, or ADRs. When the authority determines that submitted data are insufficient for a safety conclusion — a common finding given the complexity of strain characterisation requirements — it issues an ADR, the nine-month clock pauses, and the applicant must respond.
The same npj Science of Food analysis found that ADRs account for roughly 47% of total evaluation time. Applicants take an average of 130 days to answer a single ADR. Many applications receive more than one. This is not a regulatory failure in the conventional sense; EFSA is doing its job. The problem is that the dossier quality arriving at the front door is often inadequate from the start, generating ADR loops that compound the delay.
For microalgae specifically, the documentation burden is unusually steep. EFSA's updated 2024 guidance — which applies to all novel food applications submitted from February 2025 — requires unambiguous taxonomic identification at the species level, a fully characterised production process, detailed compositional data across ten defined sections, and proposed use levels backed by intake modelling for the EU population. For algae products, strain characterisation sits at the centre of the safety assessment. The same genus can contain strains with radically different profiles of heavy metals, toxins, or bioactive compounds. EFSA will not accept a genus-level description where a species-level verification is achievable.
Regulatory affairs teams who have been through the process know this. Founders who have not often discover it during the suitability check phase — before scientific evaluation has even begun. The average time from submission to the start of scientific evaluation is 299 days alone.
The numbers
biology & scale-up
taxonomy · composition
avg 2.56yr + 7mo EC
biology & scale-up
taxonomy · composition
same process, earlier start
What the framework has approved
The novel food framework in Europe is not, in itself, hostile to algae. Eleven microalgae-derived products had cleared the process by August 2024. But the conditions of use attached to each are product-specific, applicant-specific, and often species-strain-specific.
The data exclusivity trap
This creates a compounding dynamic. A well-resourced, research-capable company navigates the process at cost and then locks out follow-on entrants for five years. A less resourced company either waits for that exclusivity window to expire — and then still needs to generate independent safety data to file — or funds an entirely parallel dossier from scratch with no guarantee of timeline or outcome. For species where no prior authorisation exists, there is no shortcut at all.
Regulatory status by species
The traditional food notification route is available for products with a documented history of safe use in a non-EU country for at least 25 years. Chlorella vulgaris and Chlorella pyrenoidosa are already listed as traditional foods in the EU catalogue and do not require novel food authorisation. For companies working with less-consumed species — Nannochloropsis, Tisochrysis lutea, marine diatoms — this path does not apply.
| Species | EU pathway | Auth. required? | Current status |
|---|---|---|---|
| Chlorella vulgaris | Traditional food | No | Listed in EU catalogue |
| Chlorella pyrenoidosa | Traditional food | No | Listed in EU catalogue |
| Schizochytrium spp. | Novel food (authorised) | Yes | Authorised (DHA oil) |
| Euglena gracilis | Novel food (authorised) | Yes | Authorised · Data exclusivity Apr 2029 |
| Haematococcus pluvialis | Novel food (authorised) | Yes | Authorised (astaxanthin meal) |
| Nannochloropsis spp. | Novel food (required) | Yes | No authorisation — full dossier required |
| Tisochrysis lutea | Novel food (required) | Yes | No authorisation — full dossier required |
| Marine diatoms | Novel food (required) | Yes | No prior authorisation exists |
The implication for algae strategy
European market access for genuinely novel algae products is a three-to-six-year process, minimum, and closer to the upper end for less-characterised species. That is not an argument against pursuing it — the EU is the most valuable single market for functional food ingredients. It is an argument for making the regulatory dossier a product development output from day one, not a compliance exercise at the end.
What the process rewards, operationally, is early engagement. EFSA has a pre-submission consultation mechanism. Companies that use it — to validate their strain characterisation approach, stress-test their compositional data package, and identify ADR risks before submission — tend to move faster. The problem is that pre-submission consultation requires knowing what questions to ask, which requires regulatory expertise that most early-stage algae companies do not have in-house.
The companies that will reach the EU market at scale are the ones treating taxonomic verification, production process documentation, and compositional characterisation as parallel workstreams to cultivation R&D — not tasks that begin after the biology is solved.
The three-year clock is already running for whoever submits next. The question is how far behind the science is when they do.
SustaBloom tracks this as a strategic layer, not a legal one.